Albumin-encapsulated Nanoparticles of Naproxen Platinum(IV) Complexes with Inflammation Inhibitory Competence Displaying Effective Antitumor Activities in vitro and in vivo
Received 4 June 2021
Accepted for publication 21 July 2021
Published 14 August 2021 Volume 2021:16 Pages 5513—5529
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Yan Shen
Linming Li,1,* Yan Chen,1,* Qingpeng Wang,1 Zuojie Li,1 Zhifang Liu,1 Xuewen Hua,1 Jun Han,1 Chunxiao Chang,2 Zhengping Wang,1,3 Dacheng Li1,4
1Institute of Biopharmaceutical Research, Liaocheng University, Liaocheng, 252059, People’s Republic of China; 2Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250022, People’s Republic of China; 3Liaocheng High-Tech Biotechnology Co., Ltd, Liaocheng, 252059, People’s Republic of China; 4Shandong Provincial Key Laboratory of Chemical Energy Storage and Novel Cell Technology, Liaocheng University, Liaocheng, 252059, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Qingpeng Wang
Institute of Biopharmaceutical Research, Liaocheng University, Liaocheng, 252059, People’s Republic of China
Tel/Fax +86 635 8239773
Email [email protected]
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250022, People’s Republic of China
Email [email protected]
Background: Platinum(IV) complexes with inflammation inhibitory properties are much favored in improving antitumor activities. Nanodrug-delivery system as a preferable measure for antitumor therapy are widely explored in platinum(IV) drug delivery.
Purpose: The aim for this study was to develop novel bovine serum albumin (BSA) nanoparticles (NPs) based on naproxen platinum(IV) complexes to display a synergistic antitumor mechanism targeting cyclooxygenase-2 (COX-2), metalloproteinase-9 (MMP-9) and inducible nitric oxide synthase (iNOS).
Methods: Herein, we reported the preparation of two BSA NPs of naproxen platinum(IV) complexes, and their antitumor activities were investigated in vitro and in vivo.
Results: Both NPs possessed relatively uniform size and good stability for 30 days in aqueous solution. They exhibited prominent antitumor activities in vitro, and showed great potential in reversing drug resistance. Furthermore, these two NPs played superior tumor growth suppression in vivo in contrast to the free compounds, which were comparable to that of cisplatin and oxaliplatin, but induced lower toxic influences than platinum(II) drugs especially to spleen and liver. Moreover, the naproxen platinum(IV) NPs could decrease tumor inflammation targeting COX-2, MMP-9 and iNOs, and decreasing NO production, which would be in favor of enhancing the antitumor competence, and reducing toxicity.
Conclusion: Taken together, BSA NPs of naproxen platinum(IV) complexes demonstrated a powerful antitumor efficacy in vitro and in vivo. The platinum(IV) NPs with inflammation inhibitory competence targeting multiple enzymes reported in this work afford a new strategy for the development of antitumor therapy to overcome drawbacks of clinical platinum(II) drugs.
Keywords: bovine serum albumin nanoparticles, cyclooxygenase-2, metalloproteinases-9, inducible nitric oxide synthase, synergistic antitumor efficacy
Cancer is a major public problem worldwide and seriously threats human health and life.1,2 Chemotherapy as a systemic treatment is widely applied in the treatment of various tumors for its superior effectiveness, especially to the tumors at advanced stages. Nanodrug-delivery system (nano-DDS) provides a new effective tool for chemotherapy in clinics.3 Nanodelivery of various chemotherapeutic drugs has received tremendous attention in the past decades owing to their superiority in improving drug solubility, increasing accumulation in tumors, reducing side effects and prolonging blood circulation time. Moreover, taking advantage of the enhanced permeability and retention (EPR) effect in tumor tissues, nanoparticles (NPs) facilitate drug targeting to tumor tissues, and further influence their activities and toxic properties.4,5 The investigation on nano-DDS of chemotherapeutics has been a hot topic in cancer treatments.
Platinum drugs play a pivotal role in cancer treatment in clinics. Especially cisplatin, carboplatin, and oxaliplatin are highly effective in cancer chemotherapy.6,7 The injection of platinum(II) drugs usually involves a high peak of drug level above the maximum tolerable concentration (MTC) in the plasma, rapid elimination and low bioavailability, which causes severe side effects, drug resistance, etc, and further hinders their scope of use. Nano-DDS exhibits unique advantages in drug controlled release and is extensively exploited for platinum drug delivery.8 Nevertheless, low lipophilicity and poor stability of traditional platinum(II) drugs limit the formation of the NPs especially when injected into the bloodstream.9,10 Platinum(IV) complexes as prodrugs of platinum(II) drugs with d6 octahedral geometry show rather enhanced lipophilicity and stability.11,12 Large amounts of platinum(IV) based nano-DDS have been developed and exhibited significant superiority over free platinum drugs.
Serum albumin nanocarriers represent one of the most promising carriers recently generated because of their good biocompatibility, low immunogenicity, biodegradability, and favorable toxicological profiles.13,14 Moreover, albumin nanocarriers are potent in improving the stability of sensitive therapeutic cargos and possess much potential in targeting tumor cells.15 Especially, the market of serum albumin nanomedicine Abraxane® (paclitaxel) lightens the enthusiasm of researchers on serum albumin nanoparticles.16 Bovine serum albumin (BSA) with high sequence homology (76.52%) to human serum albumin (HSA), wide source and low cost has been widely investigated.17–20 Whereas, the serum albumin NPs loaded platinum(IV) drugs were seldom investigated. Moreover, it has been proven that the conjunction of platinum(IV) drugs with albumin could significantly decrease the reduction rate and enhance stability of drugs in whole blood.21 Thereby, it is of great interest for us to design a series of BSA nanoparticle-loaded platinum(IV) complexes and further investigate their antitumor properties.
Inflammation is an important hallmark in cancer progression associated with the occurrence, development and metastasis of malignancy.22,23 Inflammation inhibition during the cancer treatment plays essential roles in improving efficacy of chemotherapeutics.24,25 Several non-steroid anti-inflammatory drugs (NSAIDs) like aspirin, ibuprofen, indomethacin, and flurbiprofen, which display dramatic anti-inflammatory properties mainly targeting cyclooxygenases (COXs), have been incorporated with the platinum(IV) system to form a series of promising complexes.26–38 The mechanism detection discloses that these complexes display prominent inflammation inhibitory properties besides causing serious DNA damage. Our previous work reported a series of mono-naproxen platinum(IV) complexes with prominent antitumor activities, which showed great potential in inhibiting tumor migration by synergistic inhibition of COX-2 and matrix metalloproteinases (MMPs).39 More recently, Guo and Wang’s group reported the efficient antitumor performance of dual naproxen platinum(IV) complex 2.40 It targeted COX-2 and PD-L1 via multiple pathways to significantly inhibit the immune escape of tumor cells and finally improve antitumor efficacy. Thereby, naproxen platinum(IV) complex represents a promising scaffold for further development of novel platinum drugs.
In view of the potent activities of NSAID derived platinum(IV) complexes and the advantages of nano-DDS, nanoparticles of NSAID platinum(IV) would be effective to facilitate cellular uptake and improve apoptosis-inducing ability.32 However, nano-DDS based on biocompatible BSA loading such platinum(IV) complexes has not been reported. Inspired by these observations and as a continuation of our interest in developing new platinum antitumor drugs,41–43 two dual naproxen platinum(IV) complexes 1 and 2 with oxaliplatin and cisplatin cores were prepared (Figure 1). Then, BSA nanoparticles 1-NPs and 2-NPs loaded with dual naproxen platinum(IV) complexes were designed, prepared, and characterized. Their antitumor activities and toxic properties were evaluated in vitro and in vivo, and their likely antitumor mechanisms were also detected.
Materials and Methods
All reactions were carried out under an atmosphere of nitrogen in flame-dried glassware with magnetic stirring unless otherwise indicated. Cisplatin and oxaliplatin were purchased from Boyuan Chemical Co. Ltd (Jinan, China). Other reagents were obtained from Sigma, Aladdin, Innochem, and J&K Scientific Ltd. 1H NMR and 13C NMR spectra were recorded on a Bruker (500 MHz and 125 MHz). All NMR chemical shifts were referenced to residual solvent peaks or TMS as an internal standard. All coupling constants J were quoted in Hz. Mass spectra (MS) were obtained on a Shimadzu LC-MS/MS 8040 mass spectrometer with ESI ionization. The particle size (Z-average), polydispersity index and zeta potential were detected by dynamic light scattering (DLS, Zetasizer Nano ZSP, Malvern, UK). Transmission electron microscope (TEM) was recorded on JEM-2100 (JEOL, Japan). The BSA was purchased from J&K. Genomic DNA mini-preparation kit, was purchased from Beyotime, China. UV-vis spectra were measured on a Scinco S-3100 UV-vis spectrophotometer. The fluorescence spectra were recorded on a Hitachi F-7000. The cells were purchased from Procell Life Science & Technology Co., Ltd (China).
Preparation of Compound 1
Complex 1 was prepared as reported in our previous work.39 A solution of naproxen (134 mg, 0.58 mmol) and N,N,N’,N’-tetramethyl-O-(benzotriazol-1-yl)uranium tetrafluoroborate (TBTU) (187 mg, 0.58 mmol) in dry DMF 5 mL was stirred at room temperature for 10 min after injection of N,N,N-triethylamine (TEA) (80 μL, 0.58 mmol). Subsequently, oxoplatin O1 (86 mg, 0.20 mmol) was added, and the reaction mixture was stirred vigorously at 50°C for 48 h in the dark. After the reaction completed, the solvent was evaporated and the residue was purified by silica gel column chromatography using dichloromethane-methanol (80: 1, v/v). Complex 1 was obtained as white solid (54.8 mg, 32%), with 97.9% purity as determined by HPLC (methanol-H2O, 70%).
1H NMR (500 MHz, DMSO-d6) δ 7.80–7.65 (m, 6H), 7.39–7.34 (m, 2H), 7.27 (s, 2H), 7.15–7.10 (m, 2H), 3.92–3.82 (m, 8H), 2.26–2.03 (m, 2H), 1.98–1.78 (m, 2H), 1.46–1.36 (m, 6H), 1.26–1.20 (m, 2H), 1.16–1.07 (m, 2H), 0.77–0.49 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δ 182.2, 163.6, 157.5, 137.3, 133.6, 129.5, 128.8, 127.1, 127.0, 125.8, 119.0, 106.1, 61.3, 55.6, 46.9, 31.2, 23.5, 19.6. ESI-MS: calcd for [M + H]+: 857 (M = C36H40N2O10Pt), found: 857.39
Preparation of Compound 2
A solution of naproxen (134 mg, 0.58 mmol) and TBTU (187 mg, 0.58 mmol) in dry DMF 5 mL was stirred at room temperature for 10 min after injection of TEA (80 μL, 0.58 mmol). Subsequently, oxoplatin O2 (67 mg, 0.20 mmol) was added, and the reaction mixture was stirred vigorously at 50°C for 48 h in dark. After the reaction completed, the solvent was evaporated and the residue was purified by silica gel column chromatography using dichloromethane-methanol (70:1, v/v). Complex 2 was obtained as white solid (36.4 mg, 24%). 98.1% purity determined by HPLC (methanol-H2O, 70%).
1H NMR (500 MHz, DMSO-d6) δ 7.82–7.68 (m, 6H), 7.48 (d, J = 8.4 Hz, 2H), 7.27 (s, 2H), 7.13 (dd, J = 8.9, 1.9 Hz, 2H), 6.55 (s, 6H), 3.86 (s, 6H), 3.07 (d, J = 7.0 Hz, 2H), 1.41 (d, J = 7.1 Hz, 6H). 13C NMR (126 MHz, DMSO-d6) δ 182.47, 157.40, 137.84, 133.51, 129.55, 128.83, 127.47, 126.82, 125.97, 118.83, 106.14, 55.61, 46.88, 46.22, 20.29. ESI-MS: Calcd. for [M+H]+: 759 (M = C28H32Cl2N2O6Pt), found: 759.
Preparation of Nanoparticles 1-NPs and 2-NPs
Briefly, free compound 1 or 2 (5 mg, 1.0 eq.) was dissolved in 1.5 mL ethanol containing 5% dichloromethane under continuous ultrasonication. The organic solution was added dropwise into 15 mL deionized water with BSA (complex 1 or 2/BSA; 2.0 eq./1.0 eq., 3.0 eq./1.0 eq., 5.0 eq./1.0 eq. and 7.5 eq./1.0 eq.), and the mixture was stirred for 20 min vigorously at room temperature. Then, the organic solvent was evaporated under vacuum to about 12 mL. The obtained NPs were then homogenized by a D-3L homogenizer (PhD, USA) at optimal homogenization conditions of 100 MPa for 15 min to reduce the particle size. Then, deionized water was supplied, and solution of nanoparticles 15 mL was obtained.
Characterization of NPs
The particle size (Z-average), polydispersity index and zeta potential of NPs were detected by dynamic light scattering (DLS, Zetasizer Nano ZSP, Malvern, UK) with an integrated 4 mV He-Ne laser (λ=633 nm) and the backscattering detection (scattering angle θ=173º) at set temperature. Experiments were performed in triplicate.
The morphology of NPs was analyzed by transmission electron microscope (TEM, JEM-2100, JEOL, Japan). One drop of NP (100 µg/mL of free complex) was placed on a carbon-coated copper grid and stained with uranyl acetate (2%, w/v). The TEM observations were performed at an accelerating voltage of 80 kV.
In vitro Cellular Cytotoxicity Assays
The naproxen platinum(IV) nanoparticles 1-NPs, 2-NPs and free compounds 1, 2 were evaluated for antitumor activities against four tumor cell lines including human lung cancer (A549), human ovarian cancer (SKOV-3), murine colon cancer (CT-26) and a cisplatin-resistant cell line A549R, and a human normal liver cell line LO-2 using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay with cisplatin, oxaliplatin, and naproxen as reference drugs.45 A BSA nanoparticle without drugs was prepared and tested as a vehicle. The cells were maintained in RPMI1640 medium containing 10% FBS in a humidified atmosphere containing 5% CO2 at 37°C. The A549R was maintained with 2 μg/mL cisplatin. Phosphate buffered saline (PBS) contained 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 2 mM KH2PO4 (pH 7.4). MTT solution at concentration of 5 mg·mL−1 for MTT assays was prepared before use.
Cells were seeded in 96-well plates at 5000 cells per well in 100 μL of complete medium, and incubated for 24 h in a 5% CO2 atmosphere at 37°C. Then freshly prepared culture medium 100 μL containing drugs at different concentrations were added. The cells were further incubated for another 48 h or 72 h. After that, freshly prepared MTT solution (5 mg·mL−1) 20 μL was added. The resultant mixtures were incubated for 4 h to allow viable cells to reduce the yellow tetrazolium salt into dark blue formazan crystals. After removal of the medium, formazan was dissolved in DMSO (150 μL) and quantified by a microplate reader (570 nm). The IC50 values were calculated using GraphPad Prism 6 based on three parallel experiments.
In vivo Antitumor Assay
Male BALB/c mice (18–20 g) were purchased from the Laboratory Animal Center, Shandong University (Shandong, China). This study was performed in strict accordance with the NIH guidelines for the care and use of laboratory animals (NIH Publications No. 8023, revised 1978), and was approved by the Institute Animal Ethics Committee of Liaocheng University (Liaocheng, China).
Murine CT-26 cells (5×105) suspended in PBS were injected subcutaneously into the right flank of BALB/c mice and therapy was started when tumor nodules were palpable (day 6). The mice were divided into seven groups randomly, saline; cisplatin (2 mg Pt/kg, i.v.); oxaliplatin (4 mg Pt/kg, i.v.); compound 1 (4 mg Pt/kg, i.p.), 1-NPs (4 mg Pt/kg, i.v.); compound 2 (2 mg Pt/kg, i.p.), 2-NPs (2 mg Pt/kg, i.v.). Freshly prepared solutions of drugs were administered four times, on days 6, 9, 12, and 14 posttumor inoculation. Tumor volume (V) was determined as V=L×W2/2, where the length (L) and width (W) were measured. At day 15, 24 h after the last drug application, the mice were euthanized. The tumors were excised and weighed. The blood and tissues including liver, heart, spleen, lung, and kidney were collected. Then, tissues were formalin-fixed in 4% formaldehyde overnight, paraffin-embedded, and cut with a microtome (5 μm sections) for hematoxylin and eosin (H&E) staining and immunohistochemical detection.
Determination of NO Production
The cells RAW 264.7 (1×106 cells/well) in 100 μL media were preincubated in 96-well plates for 24 h. Then the media was removed. Fresh media 100 μL containing lipopolysaccharide (LPS) (1 μg/mL) and drug at different concentrations were added and the cells were further incubated for 24 h. Then, the growth medium 75 μL was mixed with the same volume of Griess reagent for 5 min and absorbance was measured at 570 nm. The accumulation amount of nitrite was determined as an index of NO. Three replicates were performed for all the treatments.
AST, ALT, BUN and CRE Detection
The blood of mice was collected in Eppendorf tubes and centrifuged at 1500 g for 15 min to collect serum samples. Then the AST, ALT, BUN and CRE were detected using enzyme-linked immunosorbent assay kits according to the manufacturer’s instructions: serum aspartate aminotransferase (AST ELISA kit, Nanjing Jiancheng Bioengineering Institute, China), alanine aminotransferase (ALT ELISA kit, Nanjing Jiancheng Bioengineering Institute, China), blood urea nitrogen (BUN ELISA kit, Nanjing Jiancheng Bioengineering Institute, China) and creatinine (CRE ELISA kit, Nanjing Jiancheng Bioengineering Institute, China). The OD values were recorded on an automatic microplate reader (Tecan Spark).
The COX inhibitory experiment was carried out using a cyclooxygenase 2 inhibitor screening kit (Beyotime, China) according to the manufacturer’s protocol. The rhCOX-2 was applied in the experiments. The inhibitions of compounds 1 and 2 at different concentrations (5, 20 μM) and naproxen at corresponding concentrations (10, 40 μM) to COX-2 were tested. Then the reduced systems of complexes 1 and 2 with ascorbic acid (AsA) (Compd.-AsA) were prepared by incubation of compound 1/2 solution under treatment of AsA (1 mM) for 48 h to allow the platinum(IV) to totally convert to platinum(II) complexes with release of two equivalent of naproxen. The compound 1-AsA and compound 2-AsA were also tested at concentrations of 5 and 20 μM. Then, cisplatin and oxaliplatin at 20 μM were also evaluated. The sample with no rhCOX-2 inhibitor was evaluated as blank, and celecoxib was used at the suggested concentration in the protocol (100 nM) as positive reference sample.
Tumor tissues of 1-NPs, 1, oxaliplatin and saline treated groups were stained using MMP-9 and iNOS staining assays according to the standard procedure. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded organism sections. Following deparaffinization and hydration, sections were immersed into citrate buffer, boiled in a microwave for antigen repair and blocked in 10% normal goat serum (Sigma, USA) for 60 min. Then, sections were incubated at 4°C with primary antibody MMP-9 (Servicebio, China; DILution ratio, 1:100) or iNOS (Proteintech; DILution ratio, 1:800) overnight. Subsequently, sections were washed in PBS and incubated with goat anti-mouse IgE-HRP secondary antibody (Servicebio, China; DILution ratio, 1:200) for 50 min at room temperature. After washed with PBS, the sections were visualized with 3,3ʹ-diaminobenzidine (DAB) (Servicebio, China), and counterstained using hematoxylin. The MMP-9 and iNOS index was calculated as the mean optical density (percent) by choosing five random fields with an optical microscope.
Accumulation of Platinum in Whole Cells and DNA
The CT-26 cells were seeded in 6-well cell culture plate and incubated for 12 h at 37 °C. Then the cells were treated with platinum compounds (100 μM) including nanoparticles 1-NPs, 2-NPs, complexes 1, 2 and reference drugs cisplatin, oxaliplatin for 10 h in incubator. After that, all the cells were harvested, collected and washed for three times with PBS. Approximately one million cells were mineralized with 70% HNO3 (LC), and the platinum in cells was determined with ICP-MS. Results were presented as the mean of three determinations for each data point. To test the DNA platination of the tumor cells, the DNA of approximately one million cells was isolated with a Genomic DNA Mini-Preparation Kit (Beyotime, China). Then the DNA was mineralized with 70% HNO3 and measured by ICP-MS.
Platinum in Tumor, Liver and Kidney
Tissues including tumor, liver and kidney from nanoparticles 1-NPs, 2-NPs, free compounds 1, 2, reference drugs cisplatin and oxaliplatin treated groups were collected and mineralized with 70% HNO3 (LC). The platinum in tissues was determined with ICP-MS.
Fluorescence and UV-vis Spectra Assays for BSA Interaction
The fluorescence spectra were recorded on a Hitachi F-7000 spectrofluorometer using a quartz cell of 1.00 cm. The slits of both excitation and emission were 5.0 nm. The quenching spectra of BSA were recorded by the gradually addition of compound 1/2 (0.0, 8.0, 14.0, 20.0 μM) to BSA solution (4.0 μM) in buffer (10 mM Tris-HCl/10 mM NaCl, pH 7.4). The well-mixed solutions were holding for 15 min for equilibrium and tested under excitation of 298 nm at a scan rate of 300 nm·min−1 under excitation of 280 nm. The fluorescence spectra of free complexes (20.0 μM) were also detected.
Then, the UV-vis spectra were also employed to testify the BSA interaction of compounds 1 and 2. The solution of BSA (10 μM) was recorded as line a. The solution of BSA-Compound (1:1) (10 μM) was recorded as line b. The solution of compound (10 μM) was recorded as line c. Line d was obtained by the subtraction of line b and line c.
Results and Discussion
The Synthesis of Naproxen Platinum(IV) Complexes
Naproxen platinum(IV) complexes 1 and 2 were prepared by the condensation of naproxen with oxoplatins O1 and O2 in the presence of TBTU and TEA (Figure S1). Oxoplatins O1 and O2 were obtained by the oxidation of cisplatin, oxaliplatin with hydrogen peroxide as reported in our previous work.46,47
The Particle Size, Zeta Potential and Morphology
The BSA nanoparticles of complexes 1 and 2 were prepared for four drug/BSA ratios (complex 1 or 2/BSA; 2.0 eq./1.0 eq., 3.0 eq./1.0 eq., 5.0 eq./1.0 eq. and 7.5 eq./1.0 eq.) as shown in Tables S1 and S2. The results revealed that drug/BSA ratio of 3.5:1 is suitable for preparing the 1-NPs due to the minimum size (280.2±6.5 nm), narrow distribution (PDI=0.32±0.03) and high zeta potential (−29.5±0.3 mV). Meanwhile, drug/BSA ratio of 5.0:1 is suitable for preparing the 2-NPs, which affords particles with minimum size of 273.1±1.5 nm, low PDI of 0.30±0.02, and high zeta potential of −22.8±0.8 mV (Figure 2). It was proven that the NPs with negative surface charge would show preferential uptake at the tumor site with higher cationic charge density in comparison with normal organs.48,49 Thereby, the negative zeta potential of the NPs indicates that 1-NPs and 2-NPs keep stable in aqueous environment, and these facts might be a factor accounting for the high accumulation of nanoparticles in tumor cells and tissues as depicted by cellular uptake results (see, tumor target properties section). Subsequently, the morphology of 1-NPs and 2-NPs were observed by TEM. Both particles are mostly uniform spheres in shape without sign of agglomeration with size of 275 nm and 283 nm respectively. These results coincide with the size analyzed by DLS.
Figure 2 Mean hydrodynamic diameter determined by DLS, and TEM images of 1-NPs (A–C) and 2-NPs (D–F).
Abbreviations: DLS, dynamic light scattering; TEM, transmission electron microscope; NPs, nanoparticles.
To illustrate the assembled mechanism of 1-NPs and 2-NPs, the interaction of complexes 1 and 2 with BSA were investigated by fluorescence and UV-vis absorption spectroscopies. The fluorescence spectroscopy is widely applied in the exploration of structural and conformational changes of proteins. The fluorescence spectra in Figure S2 demonstrate that the emission fluorescence of BSA at 340 nm is quenched with the addition of platinum(IV) complexes 1 or 2. These facts indicate that complexes 1 and 2 could combine with BSA noncovalently. Then, UV-vis spectra of BSA in the absence and presence of compounds 1 and 2 (Figure S3) were measured to determine the binding mechanism. The differential absorption spectra (curve d) between compound 1/2-BSA complex (curve a) and platinum(IV) complex 1/2 (curve c) are apparently different from the spectra of BSA (curve b) at equivalent concentrations. Conclusively, the binding of platinum(IV) complexes 1 and 2 with BSA is a static quenching process due to the complex formation.
The long-term storage stability studies of 1-NPs and 2-NPs were performed at 4°C with size measurement by DLS. The nanoparticles 1-NPs and 2-NPs exhibit no dramatic change of size, PDI and zeta potential during 30 days storage at 4°C, pH=7.4. The results in Figure 3 (Table S3) manifested that the mean hydrodynamic diameter of 1-NPs was 266.0±16.7 nm with a narrow distribution (PD =0.37±0.01) on day 30, which was similar to the original size of 280.2±6.5 nm. Meanwhile, the size of 2-NPs was approximately 297.1±4.9 nm at 30 days, which had no significant difference compared to the size at day 0 (273.1±1.5 nm). Moreover, the PDI and zeta potential of both nanoparticles also kept stable during the 30 days storage (Table S8). All these facts demonstrate that 1-NPs and 2-NPs could remain stable for at least 30 days in the aqueous phase under condition of T=4°C, pH=7.4. Then, to detect the influence of temperature on stability, 1-NPs and 2-NPs were also evaluated at 25°C and 37°C. Results in Tables S4, S5, S9 and S10 revealed that the increased temperature remarkably decreased the stability of NPs. The size of both 1-NPs and 2-NPs increased significantly at day five both at 25°C and 37°C accompanied with the drop Zeta potential. To further detect the influence of pH, the change of size, PDI and zeta potential of NPs were also tested at pH=6.4 (the pH in TME) at 4°C and 37°C. Results in Tables S6, S7, S11 and S12 manifested that low pH led to no significant change of 1-NPs and 2-NPs at 4°C in seven days. However, accelerated change of size and zeta potential of 1-NPs and 2-NPs were observed at 37°C (pH=6.4) in comparison with that in pH=7.4. Thereby, the optimized storage conditions of the BSA NPs in this work was T=4°C, pH=7.4.
Figure 3 The particle size and PDI of (A) 1-NPs and (B) 2-NPs during storage of 30 days (pH=7.4, T=4°C).
Abbreviations: PDI, polydispersity index; NPs, nanoparticles.
Antitumor Activity in vitro
The in vitro antitumor activities of BSA-based naproxen platinum(IV) nanoparticles 1-NPs and 2-NPs and free complexes 1 and 2 on four tumor cell lines including human ovarian cancer (SKOV-3), murine colon cancer (CT-26), human lung cancer (A549), and a cisplatin-resistant cell line A549R were evaluated by MTT assay with cisplatin and oxaliplatin as reference drugs. Then, a human normal liver cell LO-2 was also evaluated and the results were given as IC50 values in Table 1. To evaluate the effects of incubation time on antitumor activities, the IC50 values for 1, 2, 1-NPs and 2-NPs against SKOV-3 were tested after 48 h and 72 h incubation. It could be observed that the incubation time prolonging from 48 h to 72 h induces no dramatic change of the IC50 values. Thereby, the 48 h incubation time was selected and applied in the following evaluation.
Table 1 Cytotoxicity Profiles of Naproxen Platinum(IV) Complexes Toward Four Carcinoma Cell Lines, and One Normal Human Cell Line Expressed as IC50 (μM)
Free naproxen platinum(IV) hybrids 1 and 2 display effective antitumor activities to all tumor cells with IC50 values below 11.3 μM. Especially, complex 2 with cisplatin core exhibits promising activities (IC50 ≤0.32 μM) in vitro, which are significantly more effective than cisplatin and oxaliplatin. However, the free compounds possess rather poor solubility in water with high Alog P-values for complexes 1 (6.263) and 2 (6.182) respectively. Thereby, it is of great importance to prepare nanoparticles of such naproxen platinum(IV) complexes, which would improve solubility of drugs and further influence their activities.
As disclosed in Table 1, the BSA nanoparticles 1-NPs and 2-NPs loaded naproxen platinum(IV) complexes 1 and 2, respectively show effective antitumor activities, while the vehicle BSA exhibits no toxicity to tumor cells. Notably, all the IC50 values for 2-NPs with cisplatin platinum(IV) complex are lower than reference drug cisplatin, meanwhile 1-NPs with oxaliplatin core also display comparable or even better activities than oxaliplatin. Furthermore, 1-NPs and 2-NPs show much potential in overcoming drug resistance of A549R with low RF values of 0.4 and 0.7, which are significantly lower than cisplatin (RF=2.6) and free complex 1 (RF=1.2). Then, a normal cell line LO2 was tested to judge the toxicities of tested NPs to normal cells. Tumor selectivity index (SI) is determined as a ratio of the IC50 of LO-2 to the average IC50 of tumor cells.39,43 Nanoparticles possess dramatically improved SI values in comparison with the free complexes that 1-NPs and 2-NPs afford high SI values of 3.9 and 3.0 which are over 2.0–5.6 times higher than compounds 1 (SI=1.5) and 2 (SI=0.7) as well as platinum(II) drugs cisplatin (SI=1.1) and oxaliplatin (SI=1.0). These facts indicate the low toxicities of the prepared BSA nanoparticles to normal cells.
Ultimately, BSA based naproxen platinum(IV) nanoparticles 1-NPs and 2-NPs display prominent antitumor activities to all tested tumor cells and exhibit much potential in overcoming drug resistance of cisplatin. Both nanoparticles show low toxicities to normal cells in contrast to cisplatin and oxaliplatin as well as the free platinum(IV) complexes 1 and 2. The antitumor activities in vivo and action mechanism of the NPs were investigated in the following experiments.
Antitumor Efficacy in vivo
Colonic carcinoma as one of the most common cancers worldwide is a major cause of morbidity and mortality.50 Platinum drugs occupy an important position in colonic carcinoma treatment. In addition, naproxen has been proven to be favorable for treating colonic carcinoma to combine with platinum drugs. Herein, BALB/c mice bearing CT-26 homograft tumors were selected as models to study the effectiveness of BSA nanoparticles 1-NPs and 2-NPs to compare with free naproxen platinum(IV) complexes 1 and 2, using cisplatin and oxaliplatin as reference drugs. Complex 1 and 1-NPs with oxaliplatin core and oxaliplatin were administrated at dosage of 4 mg Pt/kg. Then, cisplatin was given at a low dosage of 2 mg Pt/kg taking its highly toxic properties in consideration, and the cisplatin-derived compound 2 and 2-NPs were also administrated at the same dosage. The nanoparticles 1-NPs, 2-NPs and platinum(II) drugs cisplatin and oxaliplatin were administrated via intravenous injection (i.v.) with saline as blank, while free complexes 1 and 2 were administrated via intraperitoneal injection (i.p.) for their poor solubility in saline.
The results in Figure 4 showed that nanoparticles 1-NPs, 2-NPs show remarkable inhibition of the tumor growth in vivo in contrast to saline group (P<0.001), which are relatively more effective than the free compounds 1 and 2 (P<0.05), and this trend is contrary to the results in vitro. Tumor for the saline group rapidly grows to 1586 mm3 in 15 days (Figure 4A and C), while the volumes of reference drugs oxaliplatin and cisplatin groups are 477 mm3 and 399 mm3. Nanoparticles 1-NPs and 2-NPs suppress the tumor volumes to 654 mm3 and 562 mm3 effectively, which are smaller than the corresponding free complex treated groups 1 (1041 mm3, P<0.001) and 2 (836 mm3, P<0.05) respectively. Then, tumor weight was measured after the mice were sacrificed and given in Figure 4B. Tumor growth inhibition rate (TGI) as an important index to judge effectiveness of antitumor drugs was calculated as a ratio of tumor weight of the drug-treated group to that of the saline group, and was depicted above the columns. Nanoparticles 1-NPs and 2-NPs show higher TGI of 64.7% and 58.9% than free complexes 1 (TGI=45.8%, P<0.05) and 2 (TGI=41.2%, P<0.05). The hematoxylin and eosin (H&E) staining of tumor tissues in Figure 4D shows that 1-NPs, 2-NPs and free compound 1 and 2 induce obvious apoptosis and necrosis in tumor tissues in comparison with saline, and this evidence is similar to that in the cisplatin and oxaliplatin treated groups.
Toxicity in vivo
The potential toxicities of the nanoparticles were assessed systematically during the treatment in vivo to compare with free complexes, cisplatin and oxaliplatin. Body weight as a primary indicator measuring toxic properties of drugs was monitored and supplied in Figure 5A. It is disclosed that cisplatin (2 mg Pt/kg) and oxaliplatin (4 mg Pt/kg) possess the most serious toxicity to mice by inducing body weight loss of 19.8% and 16.1% in comparison with the saline group at the end of the experiment (P<0.01). Moreover, anorexia and dyskinesia, which associate with toxicity, were observed in the cisplatin and oxaliplatin treated groups for approximately eight hours after administration. In contrast, the tested groups 1-NPs and 2-NPs as well as free complexes 1 and 2 induce no apparent signs of muscle loss, dehydration, anorexia, locomotor impairment or other unusual symptoms during the treatment, and cause rather lower weight loss of mice (0.2%−10.7%) than cisplatin and oxaliplatin (P<0.01). These facts reflect the lower toxic effects of naproxen platinum(IV) nanoparticles and free compounds in comparison with platinum(II) drugs. Furthermore, nanoparticles possess reduced toxic properties in comparison with free naproxen platinum(IV) complexes that the loss of body weight for nanoparticle 2-NPs (5.6%) is rather lower than free compound 2 (10.6%) (P<0.001), meanwhile 1-NPs (2 mg Pt/kg) also induces relatively lower body weight loss (0.2%) than free complex 1 (2.5%).
The toxic effects of drugs on the organs including heart, liver, spleen, lung and kidney were evaluated by H&E staining assay and organ weight indexes. The nanoparticles 1-NPs, 2-NPs, and free complexes 1, 2 as well as the reference drugs cisplatin and oxaliplatin cause no appreciable histological differences of the organs to compare with the saline group (Figure 5C). However, the organ weight indexes in Figure S4 as ratios of organ weight to body weight reveal remarkable suppressions of spleen induced by cisplatin and oxaliplatin in comparison with the saline group (P<0.01), which indicates the spleen damage caused by the platinum(II) drugs. Meanwhile nanoparticles 1-NPs and 2-NPs improve spleen indexes to some extent, and free complexes 1 and 2 induce no significant influences. These results are probably attributed to the reduced toxic properties of the nanoparticles. Then, the variations of heart, liver, lung and kidney indexes for all tested drugs are negligible in contrast to saline.
It is widely proven that nephrotoxicity, hepatotoxicity and neurotoxicity are the key factors influencing the toxicities of platinum drugs. The drug accumulation in liver and kidney were also detected. Results in Figure 5B reveal that the BSA nanoparticles have rather different distribution in liver and kidney with the free naproxen platinum(IV) compounds. The platination levels of 1-NPs and 2-NPs in liver are higher than free compounds 1 and 2 as well as oxaliplatin. Meanwhile, oxaliplatin accumulates at a remarkably higher level in the kidney than naproxen platinum(IV) complexes and nanoparticles. The different distributions manifest the different metabolic pathways of the BSA NPs with platinum(II) drugs in vivo, which would further influence toxicities. Subsequently, the nephrotoxicity and hepatotoxicity were detected by evaluating aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN) and creatinine (CRE) levels in serum. Noteworthy, oxaliplatin causes significant enhanced ALT and AST levels in comparison with saline indicating its impacts on liver function (Figure S5), although no obvious histological differences or liver index change are observed. In contrast, nanoparticles 1-NPS, 2-NPS display no significant effects on ALT and AST levels in serum. Then, free complexes 1 and 2 cause relatively high AST levels in comparison with 1-NPS and 2-NPS indicating that the BSA nanoparticles of naproxen platinum(IV) complexes exhibit lower liver toxicity than the free compounds as well as oxaliplatin. As for CRE and BUN, there are no obvious differences observed in the tested groups with the saline group. Summarily, BSA NPs of naproxen platinum(IV) hybrids display reduced toxic effects in comparison with platinum(II) drugs in vivo, especially to the spleen and liver.
Tumor Target Properties
Tumor target properties of chemotherapeutic drugs influence their antitumor activities and toxicities dramatically. To evaluate the tumor target properties of nanoparticles, the accumulation of 1-NPs and 2-NPs in CT-26 cells in vitro and in tumor tissues in vivo were tested by ICP-MS to compare with compounds 1, 2, cisplatin, oxaliplatin. Moreover, platinum drugs exert antitumor activities mainly through coordination to DNA via the platinum fragment. Therefore, the platinum accumulation in DNA of CT-26 cells was also evaluated. Results in Figure 6 manifest that nanoparticles 1-NPs and 2-NPs significantly improve the drug accumulation both in CT-26 cells in vitro and in tumor tissues in vivo in comparison with free compounds 1 and 2 as well as the platinum(II) drugs cisplatin and oxaliplatin. Nanoparticles 1-NPs and 2-NPs lead to 5.6 and 6.4 folds enhanced uptake in whole cells in contrast to 1 and 2, which are over 37.4 and 26.5 times higher than cisplatin and oxaliplatin (Figure 6A). Subsequently, 1-NPs and 2-NPs also lead to relatively higher platination level in DNA than free complexes 1, 2 and platinum(II) drugs (Figure 6B). These results also supply direct evidence of the DNA damage caused by the platinum(II) complex released from the nanoparticles. Notably, the accumulation of 1-NPs and 2-NPs in tumor tissues are 1.6 and 2.5 folds higher than 1 and 2, respectively (Figure 6C), which are also higher than cisplatin and oxaliplatin.
Figure 6 Accumulation of nanoparticles 1-NPs, 2-NPs and complexes 1, 2 in (A) CT-26 cells, (B) DNA after treatment of 10 h at concentration of 100 μM in vitro and in (C) tumor tissues in vivo.
Abbreviation: NPs, nanoparticles.
COX as the most important inflammatory factor has appeared as a promising target for reducing tumor-associated inflammation during the cancer chemotherapy treatment. Thereby, the COX inhibitory properties of naproxen platinum(IV) complexes 1 and 2, which could be released by 1-NPs and 2-NPs, were tested with naproxen and celecoxib as reference drugs. The reduced systems of complexes 1 and 2 (compound-AsA) were also evaluated, which were prepared by the incubation of compound solutions in the presence of AsA (1 mM) for 48 h to allow the platinum(IV) totally converting to divalent form. Results in Figure 7 manifest that celecoxib could effectively inhibit the activity of COX-2 to 49.5% at concentration of 100 nM. Naproxen platinum(IV) complexes 1 and 2 exhibit negligible inhibitions of COX-2 in tetravalent form even at high concentration of 20 μM, meanwhile their reduced systems compound 1-AsA and compound 2-AsA display prominent COX-2 inhibition of 65.5% and 90.3%, which are similar to naproxen (74.0%). Furthermore, the COX-2 inhibitory competence of the reduced naproxen platinum(IV) complexes is in a dose-dependent manner that low concentration of 5 μM leads to significantly less effective COX-2 inhibition than that of high dosage of 20 μM. Thereby, naproxen platinum(IV) complexes 1 and 2 as well as the nanoparticles 1-NPs and 2-NPs exert effective COX-2 inhibitory properties after reduction and release naproxen, which would decrease tumor-associated inflammation in tumor tissues and further increase antitumor activities.
Figure 7 The inhibition of compounds 1, 2, naproxen and the reduced systems of complexes 1, 2 (Compd-AsA) at different concentrations to COX-2 with celecoxib as reference drug.
Abbreviation: COX-2, cyclooxygenase-2.
iNOS Suppression and NO Production Inhibition
Nitric oxide (NO) was an important pro-inflammatory mediator in the regulation of inflammation progresses. Accumulated evidence has indicated that excessive production of NO in the tumor tissues could promote the development of inflammation and eventually lead to inflammatory tissue damage and further stimulate tumor growth and migration by inducing cell proliferation, reducing immune surveillance and promoting angiogenesis.51–55 Herein, LPS induced RAW 264.7 macrophages, which were widely used as a model for studying the inflammatory responses,56 were applied to evaluate the effects of naproxen platinum(IV) nanoparticles on the NO production and detect their potential effects on anti-inflammation. Results in Figure 8 indicate that naproxen platinum(IV) nanoparticles 1-NPs and 2-NPs could inhibit production of NO in RAW 264.7 macrophages, which are significantly more effective than naproxen, cisplatin and oxaliplatin. The conversion of complex 1 to nanoparticles 1-NPs improve the activities effectively, while both complex 2 and 2-NPs display satisfactory inhibition of NO production.
The inducible nitric oxide synthase (iNOS) as a calcium-independent isoform of nitric oxide synthase highly expresses in many tumors, and is the crucial enzyme responsible for the production of NO, which could lead to high levels of NO in the micromolar range. Moreover, there is emerging evidence showing that iNOS plays a central role in the process of tumor initiation and/or development.57,58 Thus, the expressions of iNOS in tumor issues treated by 1-NPs and free compound 1 were detected by immunohistochemistry. Results in Figure 9 reflect that oxaliplatin significantly upregulates iNOS in tumor tissues during its antitumor progress. Whereas, the expressions of iNOS in 1-NPs treated group is significantly lower than that of oxaliplatin (P<0.001). Furthermore, 1-NPs is also more effective than the free drug 1 (P<0.001) in iNOS inhibition, which is in line with the NO production inhibition in vitro.
Accordingly, the title naproxen platinum(IV) nanoparticle drugs show much potential in inhibiting NO production and iNOS expression, which would further influence tumor-associated inflammation.
Detection of MMP-9
MMPs are widely found in inflammation and various tumor tissues, and display pivotal roles in influencing tumor growth, invasion and metastasis. Moreover, MMPs play a synergic function with COXs in promotion of inflammation in tumors. MMPs have been considered as potential diagnostic and prognostic biomarkers in many types and stages of cancer.59,60 Herein, the expressions of MMP-9 in tumor tissues of 1-NPs, 1, oxaliplatin and saline groups were immunohistochemically stained and given as Figure 10. MMP-9 overexpresses in saline group with a mean optical density of 16.3±1.9%. Meanwhile, 1 and 1-NPs remarkably decrease the expression of MMP-9 to 1.9±0.5% and 2.0±0.8% respectively, which are significantly lower than oxaliplatin (6.5±0.5%). The promising MMP-9 inhibitory potential of naproxen platinum(IV) nanoparticles would put much influence on reducing inflammation in tumor tissues and improving antitumor activities.
In conclusion, two BSA-encapsulated nanoparticles 1-NPs and 2-NPs of naproxen platinum(IV) complexes 1 and 2 were prepared and evaluated for antitumor activities in vitro and in vivo. The nanoparticles possessed relatively uniform size and good stability for 30 days in aqueous solution (T=4°C, pH=7.4). Both of them display effective antitumor activities in vitro, and exhibit great potential in overcoming drug resistance of cisplatin with resistant factors (RF <0.68) significantly lower than cisplatin (RF=2.57). Moreover, 1-NPs and 2-NPs accumulate at higher levels in whole tumor cells, DNA and tumor tissues than cisplatin and oxaliplatin as well as free platinum(IV) complexes 1 and 2, and show low toxicity with high tumor selective indexes of 3.0 and 3.9, which are significantly more promising than cisplatin (SI=1.1) and oxaliplatin (SI=1.0). Furthermore, these two nanoparticles play superior tumor growth suppression in vivo with high TGI of 64.7% and 58.9% in contrast to free compounds 1 and 2 (45.8%, 41.7%), which are comparable to that of cisplatin and oxaliplatin, and induce lower toxic influences than platinum(II) drugs especially to the spleen and liver. The naproxen platinum(IV) nanoparticles display antitumor activities by a symmetric mechanism (Figure 1) that nanoparticles target tumor cells and would release naproxen platinum(IV) complexes 1 and 2 in cytoplasm. Then the platinum(II) core would be released after reduction, and further conjunct with DNA to cause serious DNA damage. The further mechanism detections in vitro and in vivo disclose that the inflammation in tumor tissues could be reduced through the suppression of COX-2, iNOs, MMP-9 and the decrease of NO production, which would increase the sensitivity of tumor cells to platinum drugs, prevent the development of cancer and enhance the antitumor activities of the nanoparticles. These encouraging results highlight the value of naproxen platinum(IV) nanoparticles 1-NPs and 2-NPs as antitumor agents, and further investigations based on such drugs are underway in our laboratory.
This work was supported by National Natural Science Foundation of China (No. 21807056), Natural Science Foundation of Shandong Province (No. ZR2020KH005), National Science and Technology Major Project (No. 2017ZX09201-003) and Taishan Scholar Research Foundation. This work was also technically supported by Shandong Province Collaborative Innovation Center for Antibody Drugs, Shandong Province Engineering Research Center for Nanomedicine and Drug Delivery Systems, and Shandong Province Engineering Laboratory of Anti-viral Drugs.
Zhengping Wang is an employee of Liaocheng High-Tech Biotechnology Co., Ltd, Liaocheng, China. The authors report no other potential conflicts of interest in this work.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
3. Peng Y, Chen L, Ye S, et al. Research and development of drug delivery systems based on drug transporter and nano-formulation. Asian J Pharm Sci. 2020;15(2):220–236. doi:10.1016/j.ajps.2020.02.004
4. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136–151. doi:10.1016/j.addr.2010.04.009
5. Zhao YP, Zhao YN, Ma QS, et al. Carrier-free, dual-functional nanorods via self-assembly of pure drug molecules for synergistic chemo-photodynamic therapy. Int J Nanomed. 2019;14:8665–8683. doi:10.2147/IJN.S224704
6. Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev. 2016;116(5):3436–3486. doi:10.1021/acs.chemrev.5b00597
7. Li Y, Sun Z, Cui Y, et al. Oxaliplatin derived monofunctional triazole-containing platinum(II) complex counteracts oxaliplatin-induced drug resistance in colorectal cancer. Bioorg Chem. 2021;107:104636. doi:10.1016/j.bioorg.2021.104636
8. Wang XY, Wang XH, Guo ZJ. Functionalization of platinum complexes for biomedical applications. Acc Chem Res. 2015;48(9):2622–2631. doi:10.1021/acs.accounts.5b00203
9. Callari M, Aldrich-Wright JR, de Souza PL, Stenzel MH. Polymers with platinum drugs and other macromolecular metal complexes for cancer treatment. Prog Polym Sci. 2014;39(9):1614–1643. doi:10.1016/j.progpolymsci.2014.05.002
10. Newman M, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol. 1999;43(1):1–7. doi:10.1007/s002800050855
11. Ma J, Wang Q, Huang Z, et al. Glycosylated platinum(IV) complexes as substrates for glucose transporters (GLUTs) and organic cation transporters (OCTs) exhibited cancer targeting and human serum albumin binding properties for drug delivery. J Med Chem. 2017;60(13):5736–5748. doi:10.1021/acs.jmedchem.7b00433
12. Tan XX, Li GS, Wang QP, Wang BQ, Li DC, Wang PG. Small molecular platinum(IV) compounds as antitumor agents. Prog Chem. 2018;30(6):831–846. doi:10.7536/PC171212
13. Karimi M, Bahrami S, Ravari SB, et al. Albumin nanostructures as advanced drug delivery systems. Expert Opin Drug Deliv. 2016;13(11):1609–1623. doi:10.1080/17425247.2016.1193149
14. Parodi A, Miao J, Soond SM, Rudzińska M, Zamyatnin AA
15. Hassanin I, Elzoghby A. Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance. Cancer Drug Resist. 2020;3:930–946. doi:10.20517/cdr.2020.68
16. Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst. 1993;15:141–147.
17. Nosrati H, Sefidi N, Sharafi A, Danafar H, Manjili HK. Bovine serum albumin (BSA) coated iron oxide magnetic nanoparticles as biocompatible carriers for curcumin-anticancer drug. Bioorg Chem. 2018;76:501–509. doi:10.1016/j.bioorg.2017.12.033
18. Nosrati H, Danafar H, Rezaeejam H, Gholipour N, Rahimi-Nasrabadi M. Evaluation radioprotective effect of curcumin conjugated albumin nanoparticles. Bioorg Chem. 2020;100:103891. doi:10.1016/j.bioorg.2020.103891
19. Ding C, Xu Y, Zhao Y, Zhong H, Luo X. Fabrication of [email protected] nanostructures for cell ﬂuoresce imaging and target drug delivery. ACS Appl Mater Interfaces. 2018;10(10):8947–8954. doi:10.1021/acsami.7b18493
20. Zhao Y, Cai C, Liu M, et al. An organic solvent-free technology for the fabrication of albumin-based paclitaxel nanoparticles for effective cancer therapy. Colloid Surface B. 2019;183:110394. doi:10.1016/j.colsurfb.2019.110394
21. Zheng YR, Suntharalingam K, Johnstone TC, et al. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery. J Am Chem Soc. 2014;136(24):8790–8798. doi:10.1021/ja5038269
22. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
23. Nisticò P, Ciliberto G. Biological mechanisms linked to inflammation in cancer: discovery of tumor microenvironment-related biomarkers and their clinical application in solid tumors. Int J Biol Marker. 2020;35(1_suppl):8–11. doi:10.1177/1724600820906155
24. Leon-Cabrera S, Schwertfeger KL, Terrazas LI. Inflammation as a target in cancer therapy. Mediators Inflamm. 2019;2019:1971698. doi:10.1155/2019/1971698
25. Zhang J, Zhang Y, Wang Q, et al. Interleukin‐35 in immune-related diseases: protection or destruction. Immunology. 2019;157(1):13–20. doi:10.1111/imm.13044
26. Cheng Q, Shi H, Wang H, Min Y, Wang J, Liu Y. The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells. Chem Commun. 2014;50(56):7427–7430. doi:10.1039/c4cc00419a
27. Pathak R, Marrache S, Choi JH, Berding TB, Dhar S. The prodrug platin-A: simultaneous release of cisplatin and aspirin. Angew Chem Int Ed Engl. 2014;53(7):1963–1967. doi:10.1002/anie.201308899
28. Neumann W, Crews BC, Sárosi MB, et al. Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance. ChemMedChem. 2015;10(1):183–192. doi:10.1002/cmdc.201402353
29. Ravera M, Zanellato I, Gabano E, et al. Antiproliferative activity of Pt(IV) conjugates containing the non-steroidal anti-inflammatory drugs (NSAIDs) ketoprofen and naproxen. Int J Mol Sci. 2019;20(12):3074. doi:10.3390/ijms20123074
30. Li G, Zhang J, Liu Z, et al. Development of a series of 4-hydroxycoumarin platinum(IV) hybrids as antitumor agents: synthesis, biological evaluation and action mechanism investigation. J Inorg Biochem. 2019;194:34–43. doi:10.1016/j.jinorgbio.2019.02.011
31. Wang Q, Chen Y, Li G, et al. Synthesis and evaluation of bi-functional 7-hydroxycoumarin platinum(IV) complexes as antitumor agents. Bioorg Med Chem. 2019;27(10):2112–2121. doi:10.1016/j.bmc.2019.04.009
32. Tan J, Li C, Wang Q, et al. A carrier-free nanostructure based on platinum(IV) prodrug enhances cellular uptake and cytotoxicity. Mol Pharmaceutics. 2018;15(4):1724–1728. doi:10.1021/acs.molpharmaceut.8b00070
33. Spector D, Krasnovskaya O, Pavlov K, et al. Pt(IV) prodrugs with NSAIDs as axial ligands. Int J Mol Sci. 2021;22(8):3817. doi:10.3390/ijms22083817
34. Zanellato I, Bonarrigo I, Ravera M, Gabano E, Gust R, Osella D. The hexacarbonyldicobalt derivative of aspirin acts as a CO-releasing NSAID on malignant mesothelioma cells. Metallomics. 2013;5(12):1604–1613. doi:10.1039/c3mt00117b
35. Curci A, Denora N, Iacobazzi RM, et al. Synthesis, characterization, and in vitro cytotoxicity of a Kiteplatin-Ibuprofen Pt(IV) prodrug. Inorg Chim Acta. 2018;472:221–228. doi:10.1016/j.ica.2017.07.019
36. Petruzzella E, Sirota R, Solazzo I, Gandin V, Gibson D. Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance. Chem Sci. 2018;9(18):4299–4307. doi:10.1039/c8sc00428e
37. Tolan DA, Abdel‐Monem YK, El‐Nagar MA. Anti‐tumor platinum (IV) complexes bearing the anti‐inflammatory drug naproxen in the axial position. Appl Organometal Chem. 2019;33(3):e4763. doi:10.1002/aoc.4763
38. Intini FP, Zajac J, Novohradsky V, et al. Novel antitumor platinum(II) conjugates containing the nonsteroidal anti-inflammatory agent diclofenac: synthesis and dual mechanisms of antiproliferative effects. Inorg Chem. 2017;56(3):1483–1497. doi:10.1021/acs.inorgchem.6b02553
39. Chen Y, Wang Q, Li Z, et al. Naproxen platinum(iv) hybrids inhibiting cycloxygenases and matrix metalloproteinases and causing DNA damage: synthesis and biological evaluation as antitumor agents in vitro and in vivo. Dalton Trans. 2020;49(16):5192–5204. doi:10.1039/D0DT00424C
40. Jin S, Muhammad N, Sun Y, et al. Multispecific platinum(IV) complex deters breast cancer via interposing inflammation and immunosuppression as an inhibitor of COX-2 and PD-L1. Angew Chem Int Ed Engl. 2020;59(51):23313–23321. doi:10.1002/anie.202011273
41. Wang Q, Huang Z, Ma J, et al. Design, synthesis and biological evaluation of a novel series of glycosylated platinum(iv) complexes as antitumor agents. Dalton Trans. 2016;45(25):10366–10374. doi:10.1039/C6DT01562J
42. Wang QP, Tan XX, Liu ZF, et al. Design and synthesis of a new series of low toxic naphthalimide platinum(IV) antitumor complexes with dual DNA damage mechanism. Eur J Pharm Sci. 2018;124:127–136. doi:10.1016/j.ejps.2018.08.032
43. Liu Z, Li Z, Du T, et al. Design, synthesis and biological evaluation of dihydro-2-quinolone platinum(IV) hybrids as antitumor agents displaying mitochondria injury and DNA damage mechanism. Dalton Trans. 2021;50:362–375. doi:10.1039/D0DT03194A
44. Wang QP, Li GS, Liu ZF, et al. Naphthalimide platinum(IV) compounds as antitumor agents with dual DNA damage mechanism to overcome cisplatin resistance. Eur J Inorg Chem. 2018;40(40):4442–4451. doi:10.1002/ejic.201800799
45. Wang Q, Chen Y, Li G, et al. A potent aminonaphthalimide platinum(IV) complex with effective antitumor activities in vitro and in vivo displaying dual DNA damage effects on tumor cells. Bioorg Med Chem Lett. 2019;29(20):126670. doi:10.1016/j.bmcl.2019.126670
46. Sameer AS. Colorectal cancer: molecular mutations and polymorphisms. Front Oncol. 2013;3:114. doi:10.3389/fonc.2013.00114
47. Wu Y, Hu X, Song L, Zhu J, Yu R. The inhibitory effect of a novel polypeptide fraction from arca subcrenata on cancer-related inflammation in human cervical cancer HeLa cells. Sci World J. 2014;2014:768938. doi:10.1155/2014/768938
48. Xiao K, Li Y, Luo J, et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials. 2011;32(13):3435–3446. doi:10.1016/j.biomaterials.2011.01.021
49. Sun J, Jiang L, Lin Y, et al. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides. Int J Nanomed. 2017;12:1517–1537. doi:10.2147/IJN.S122859
50. de Oliveira GA, Cheng RYS, Ridnour LA, et al. Inducible nitric oxide synthase in the carcinogenesis of gastrointestinal cancers. Antioxid Redox Signal. 2017;26(18):1059–1077. doi:10.1089/ars.2016.6850
51. Hu Y, Xiang J, Su L, Tang X. The regulation of nitric oxide in tumor progression and therapy. J Int Med Res. 2020;48(2):300060520905985. doi:10.1177/0300060520905985
52. Özenver N, Efferth T. Small molecule inhibitors and stimulators of inducible nitric oxide synthase in cancer cells from natural origin (phytochemicals, marine compounds, antibiotics). Biochem Pharmacol. 2020;176:113792. doi:10.1016/j.bcp.2020.113792
53. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002–2012. doi:10.1056/NEJM199312303292706
54. Vahora H, Khan MA, Alalami U, Hussain A. The potential role of nitric oxide in halting cancer progression through chemoprevention. J Cancer Prev. 2016;21(1):1–12. doi:10.15430/JCP.2016.21.1.1
55. Vannini F, Kashfi K, Nath N. The dual role of iNOS in cancer. Redox Biol. 2015;6:334–343. doi:10.1016/j.redox.2015.08.009
56. Zhang N, Liu C, Jin L, et al. Ketogenic diet elicits antitumor properties through inducing oxidative stress, inhibiting MMP-9 expression, and rebalancing M1/M2 tumor-associated macrophage phenotype in a mouse model of colon cancer. J Agric Food Chem. 2020;68:11182–11196. doi:10.1021/acs.jafc.0c04041
57. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009;27(31):5287–5297. doi:10.1200/JCO.2009.23.5556
58. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278(1):16–27. doi:10.1111/j.1742-4658.2010.07919.x
59. Yempala T, Babu T, Karmakar S, et al. Expanding the arsenal of PtIV anticancer agents: multi-action PtIV anticancer agents with bioactive ligands possessing a hydroxy functional group. Angew Chem Int Ed Engl. 2019;58(50):18218–18223. doi:10.1002/anie.201910014
60. Li Z, Chen Y, Liu Z, et al. Synthesis and biological evaluation of new mono naphthalimide platinum(IV) derivatives as antitumor agents with dual DNA damage mechanism. Monatsh Chem. 2020;151(3):353–367. doi:10.1007/s00706-020-02561-1
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]